Transaction DateRecipientSharesTypePriceValue
10th July 2020David P Hochman14,600Grant/award etc.$0.00
17th March 2020Barbara White15,606Open or private purchase$3.63$56,649.78
17th March 2020Robert Paul Discordia2,840Open or private purchase$3.54$10,053.60
17th March 2020Yuval Cohen4,300Open or private purchase$3.49$15,007.00
17th March 2020Craig Stuart Millian2,000Open or private purchase$4.25$8,500.00
6th February 2020David P Hochman20,000Grant/award etc.$0.00
12th November 2019Yuval Cohen1,430Open or private purchase$4.26$6,091.80
12th November 2019Barbara White3,424Open or private purchase$4.38$14,991.64
11th November 2019Robert Paul Discordia2,500Open or private purchase$4.62$11,558.50
11th November 2019Craig Stuart Millian1,000Open or private purchase$4.38$4,380.00
Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. The company was founded on December 18, 2013.


Ticker: CRBP
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1595097
Employees: 141
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals